Literature DB >> 31160074

Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.

Dimitrios Nasioudis1, Ryan Kahn2, Eloise Chapman-Davis2, Melissa K Frey2, Thomas A Caputo2, Steven S Witkin2, Kevin Holcomb2.   

Abstract

BACKGROUND: To investigate the impact of hospital surgical volume on the rate of complete gross resection for patients with advanced stage epithelial ovarian carcinoma undergoing primary debulking surgery.
METHODS: The National Cancer Data Base was used to identify patients undergoing between 2010 and 2014 for an advanced stage (III-IV) epithelial ovarian cancer. For analyses purposes facility surgical volume was divided into tertiles (high, intermediate and low). Patients with bulky stage III disease who underwent primary debulking surgery with known residual disease status were selected for further analysis.
RESULTS: A total of 8894 patients with macroscopic peritoneal disease were included. Rates of complete gross resection for patients managed in low, intermediate and high-volume centers were 41.0%, 41.6% and 43.3% respectively (p = 0.20). After controlling for year of diagnosis, age, insurance status, presence of co-morbidities, histology, size of peritoneal implants, stage, and complexity of surgery, patients undergoing primary debulking surgery at low (OR: 0.85, 95% CI: 0.74, 0.97, p = 0.013) and intermediate (OR: 0.90, 95% CI: 0.82, 0.99, p = 0.043) volume centers had a lower likelihood of achieving complete gross resection compared to those managed in high volume centers.
CONCLUSIONS: After controlling for multiple potential confounders, patients receiving surgery in high volume centers had a higher likelihood of complete gross resection following primary debulking surgery for advanced-stage epithelial ovarian cancer.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytoreductive surgery; Ovarian cancer; Residual tumor

Mesh:

Year:  2019        PMID: 31160074     DOI: 10.1016/j.ygyno.2019.05.016

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

Review 1.  Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.

Authors:  Mackenzie Cummings; Olivia Nicolais; Mark Shahin
Journal:  Diagnostics (Basel)       Date:  2022-04-14

2.  miR‑508‑3p suppresses the development of ovarian carcinoma by targeting CCNA2 and MMP7.

Authors:  Fei Guo; Kai Zhang; Meiyue Li; Lei Cui; Guoyan Liu; Ye Yan; Wenyan Tian; Fei Teng; Yanfang Zhang; Chao Gao; Jinping Gao; Yingmei Wang; Fengxia Xue
Journal:  Int J Oncol       Date:  2020-04-27       Impact factor: 5.650

3.  Trends in extent of surgical cytoreduction for patients with ovarian cancer.

Authors:  Deanna H Wong; Alexandra L Mardock; Erica N Manrriquez; Tiffany S Lai; Yas Sanaiha; Abdulrahman K Sinno; Peyman Benharash; Joshua G Cohen
Journal:  PLoS One       Date:  2021-12-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.